Synergistic bacterial compositions and methods of production and use thereof

A technology of composition and bacteria, applied in the direction of antibacterial drugs, drug combinations, medical raw materials derived from bacteria, etc., can solve the problems of non-standardization and characterization of products

Pending Publication Date: 2015-09-30
SERES HEALTH
View PDF5 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Fecal transplants are not and unlikely to be approved by the FDA because the product cannot be standardized and characterized according to regulatory requirements for identity, potency, purity, and safety

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synergistic bacterial compositions and methods of production and use thereof
  • Synergistic bacterial compositions and methods of production and use thereof
  • Synergistic bacterial compositions and methods of production and use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0170] Example 1. Construction of binary pairs in a high-throughput 96-well format. To allow high-throughput screening of binary pairs, vials of the -80°C glycerol stock were thawed and diluted to 1e8 CFU / mL. Each strain was then diluted 10X (to achieve a final concentration of 1e7 CFU / mL for each strain) into 200 μL of PBS + 15% glycerol in wells of a 96-well culture plate. Plates were then frozen at -80°C. When tested with C. difficile in CivSim, plates were removed from -80°C and thawed anaerobically at room temperature when required.

example 2

[0171] Example 2. Construction of triplets in a high-throughput 96-well format. To allow high-throughput screening of triplets, vials of the -80°C glycerol stock were thawed and diluted to 1e8 CFU / mL. Each strain was then diluted 10X (to achieve a final concentration of 1e7 CFU / mL for each strain) into 200 μL of PBS + 15% glycerol in wells of a 96-well culture plate. Plates were then frozen at -80°C. When required for analysis, when tested with C. difficile in CivSim, plates were removed from -80°C and thawed under anaerobic conditions at room temperature.

example 3

[0172] Example 3. Screening for Ecobiotics that inhibit the growth of Clostridium difficile TM Construction of CivSim assays of compositions. Overnight cultures of C. difficile are grown under anaerobic conditions in SweetB-FosIn or other suitable media for C. difficile growth. SweetB-FosIn is a complex medium composed of brain heart extract, yeast extract, cysteine, cellobiose, maltose, soluble starch, and fructooligosaccharide / chrysanthemum tang and hemoglobin, and with MOP buffer. After 24 hours of growth, the culture was diluted 100,000-fold into a complex medium suitable for growth of various anaerobic bacterial species (such as SweetB-FosIn). Next, the diluted C. difficile mixture was aliquoted into wells of a 96-well culture plate (180 μL per well). Next, 20 μL of unique binary pairs of potentially inhibitory species were added to each well at a final concentration of 1e6 CFU / mL per species. Alternatively, the assay can be tested with binary pairs of different initia...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided are therapeutic compositions containing ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Description

[0001] Cross References to Related Applications [0002] This patent application claims U.S. Provisional Patent Application No. 61 / 729,518, filed Nov. 23, 2012, U.S. Provisional Patent Application No. 61 / 729,519, filed Nov. 23, 2012, filed Nov. 23, 2012 U.S. Provisional Patent Application No. 61 / 729,520 filed November 23, 2012, U.S. Provisional Patent Application No. 61 / 729,522 filed November 23, 2012, U.S. Provisional Patent Application No. 61 / 729,524, filed November 23, 2012, U.S. Provisional Patent Application No. 61 / 729,515, filed November 23, 2012, U.S. Provisional Patent Application, filed November 23, 2012 61 / 729,517, U.S. Provisional Patent Application No. 61 / 729,525, filed November 23, 2012, U.S. Provisional Patent Application No. 61 / 729,526, filed November 23, 2012, US Provisional Patent Application No. 61 / 729,527, filed on 11 December 2011, which is hereby incorporated by reference in its entirety for all purposes. [0003] References to Sequence Listings [000...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61K45/06A61P1/00A61P31/04A23L1/30A23L33/00
CPCA61K31/00A61K35/742A61K35/744A61K35/745A61K35/747A61P1/00A61P1/12A61P31/04A61P43/00Y02A50/30A61K35/74A23L33/135A61K2300/00A23V2002/00A23V2200/32A61K35/741A23L33/127A23P10/30A61K9/0053A61K9/4891A61K38/13A61K45/06
Inventor G·冯马尔扎恩M·R·赫恩A·M·德奥诺弗里奥K·D·利特科夫斯基D·A·贝瑞D·酷克N·B·阿菲延J·G·奥宁斯
Owner SERES HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products